Nutex Health Inc. (NUTX) Form 10-Q — Nov 5, 2026
Nutex Health reported Q3 2026 revenue of $217.6 million, down 19% from $267.8 million a year ago, with quarterly net income attributable to Nutex of $40.2 million ($5.87 basic EPS) versus $55.4 million ($8.27) in Q3 2025. Nine-month results were much stronger: net income attributable to Nutex of $152.9 million and diluted EPS of $21.50, up from $8.87 a year ago — but this includes a one-time $52.3 million reduction to contract services expense from the June 2026 HaloMD contract amendment and the CMS cut of the federal IDR administrative fee from $115 to $15 per dispute.
Key figures
- Eps
- 5.87
- Revenue
- 217613000
- Net Income
- 57343000
- Total Debt
- 42726000
- Total Assets
- 1032376000
- Cash Position
- 249911000
- Shares Outstanding
- 6860794
- States
- 12
- Diluted eps q3
- 5.71
- Nine month revenue
- 644850000
- Hospital facilities
- 28
- Nine month basic eps
- 22.05
- Nine month net income
- 216423000
- Prior year q3 revenue
- 267804000
- Nine month diluted eps
- 21.5
- Prior year q3 net income
- 96799000
- Accrued arbitration expenses
- 51276000
- Hospital division q3 revenue
- 209097000
- Total arbitration cost q3 2025
- 41900000
- Total arbitration cost q3 2026
- 27800000
- Operating cash flow nine months
- 188065000
- Halommd change in estimate benefit
- 52300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.